Cross-Comparison of Cancer Drug Approvals at Three International Regulatory Agencies | Zendy

Nardin Samuel | Zendy; Subodh Verma | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cross-Comparison of Cancer Drug Approvals at Three International Regulatory Agencies

Author(s) -

Nardin Samuel,

Subodh Verma

Publication year - 2016

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.23.2803

Subject(s) - medicine , government (linguistics) , drug , cancer drugs , agency (philosophy) , family medicine , drug approval , approved drug , food and drug administration , public health , international agency , regulatory agency , cancer , pharmacology , public administration , political science , pathology , philosophy , linguistics , epistemology

The primary objective of the present study was to examine the drug approval process and the time to approval (tta) for cancer drugs by 3 major international regulatory bodies-Health Canada, the U.S. Food and Drug Administration (fda), and the European Medicines Agency (ema)-and to explore differences in the drug approval processes that might contribute to any disparities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research